http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020176276-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53f9ae4fef9594663de8b6dbfc855d79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0f9a1890fbbe4871e2bba0a9dcb5103
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95f6207f7e15da17912cc268b74b8e68
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-197
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
filingDate 2020-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9dbe09502bd6d02c57c16e1ad0da64e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69705c63f1407e6aab81b88948a21a4c
publicationDate 2020-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2020176276-A1
titleOfInvention A formulation for improving seizure control
abstract Described herein is a method of improving seizure control in a patient experiencing uncontrolled seizures persisting 10 minutes or more, comprising administering fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, at a dose of from 0.2 to 1.2 m/kg/day for a period of about 12 hours to about 7 days to a patient having been put into a therapeutic, medically-induced coma via a general anesthetic; and after about 12 hours to about 7 days, weaning the patient from the general anesthetic and assessing whether the seizure control has improved as compared to a pre-treatment time point. The patient experiencing seizures may have epilepsy or epileptic encephalopathy that has led to established status epilepticus (SE), refractory status epilepticus (RSE) or super-refractory status epilepticus (SRSE).
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11458111-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022251569-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11612574-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022217066-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11786487-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11571397-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11759440-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11634377-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11406606-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11673852-B2
priorityDate 2019-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016228454-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017056344-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017151214-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011230473-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012157392-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406422
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3337

Total number of triples: 48.